Results 1 to 10 of about 118,558 (284)

Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis

Genome Biology, 2017
Background The assessment and characterization of the gut microbiome has become a focus of research in the area of human autoimmune diseases. Ankylosing spondylitis is an inflammatory autoimmune disease and evidence showed that ankylosing spondylitis may
Chengping Wen, Zhijun Zheng, Tiejuan Shao, Lin Liu, Zhijun Xie, Emmanuelle Le Chatelier, Zhixing He, Wendi Zhong, Yongsheng Fan, Linshuang Zhang, Haichang Li, Chunyan Wu, Changfeng Hu, Qian Xu, Jia Zhou, Shunfeng Cai, Dawei Wang, Yun Huang, Maxime Breban, Nan Qin, Stanislav Dusko Ehrlich   +20 more
doaj   +2 more sources

Ankylosing Spondylitis

Journal of Ophthalmic and Vision Research, 2021
The seronegative spondyloarthropathies are a group of autoimmune inflammatory diseases lacking rheumatoid factor or antinuclear antibody in their serum. They include ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis, spondylitis associated with Crohn’s disease and ulcerative colitis, and undifferentiated spondyloarthropathies ...
Nazanin Ebrahimiadib, Sahar Berijani, Mohammadreza Ghahari, Fatemeh Golsoorat Pahlaviani   +3 more
openaire   +5 more sources

Factors affecting employment in Japanese patients with ankylosing spondylitis (AS) [PDF]

BMC Rheumatology
Background Ankylosing spondylitis (AS) often affects individuals during their most productive working years. However, few studies have investigated factors influencing employment in Japanese AS patients.
Hoshiko Furusawa, Kurisu Tada, Eri Hayashi, Hisashi Inoue, Shigeto Kobayashi, Ken Yamaji, Naoto Tamura   +6 more
doaj   +2 more sources

Spine Fractures of Patients with Ankylosing Spondylitis and Diffuse Idiopathic Skeletal Hyperostosis: Fracture Severity and Injury-Related Mortality at a Level I Trauma Center [PDF]

Asian Spine Journal, 2023
Study Design Retrospective review of prospectively collected cohort. Purpose To identify differences in treatment and mortality of spine fractures in patients with ankylosing conditions of the spine. Overview of Literature Ankylosing spondylitis (AS) and
Stephen Ryan Chen, Maria Amelia Munsch, Joseph Chen, Brandon Keith Couch, Richard Alan Wawrose, Anthony Abimbade Oyekan, Joshua Adjei, William F. Donaldson, Joon Yung Lee, Jeremy DeWitt Shaw   +9 more
doaj   +1 more source

Primary Biliary Cholangitis with Ankylosing Spondylitis

The Korean Journal of Gastroenterology, 2022
Primary biliary cholangitis is a chronic inflammatory autoimmune liver disease that is characterized by a positive antimitochondrial antibodies test and progressive destruction of the small intrahepatic bile duct.
Young Mi Hong, Ki Tae Yoon, Mong Cho
doaj   +1 more source

Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis

Nature Medicine, 2023
Autoimmunity is intrinsically driven by memory T and B cell clones inappropriately targeted at self-antigens. Selective depletion or suppression of self-reactive T cells remains a holy grail of autoimmune therapy, but disease-associated T cell receptors (
O. Britanova, Kseniia R Lupyr, D. B. Staroverov, I. Shagina, A. A. Aleksandrov, Y. Y. Ustyugov, Dmitry V. Somov, A. Klimenko, N. Shostak, I. Zvyagin, Alexey V. Stepanov, E. Merzlyak, A. N. Davydov, M. Izraelson, E. Egorov, Ekaterina A. Bogdanova, A. Vladimirova, Pavel A Iakovlev, D. Fedorenko, R. Ivanov, V. I. Skvortsova, Sergey Lukyanov, D. Chudakov   +22 more
semanticscholar   +1 more source

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Annals of the Rheumatic Diseases, 2022
Objectives To evaluate the efficacy and safety of upadacitinib, a Janus kinase inhibitor, in patients with active ankylosing spondylitis (AS) with an inadequate response (IR) to biological disease-modifying antirheumatic drugs (bDMARDs).
D. van der Heijde, X. Baraliakos, J. Sieper, A. Deodhar, R. Inman, H. Kameda, Xiaofeng Zeng, Y. Sui, X. Bu, A. Pangan, P. Wung, I. Song   +11 more
semanticscholar   +1 more source

Cost-of-illness of rheumatoid arthritis and ankylosing spondylitis [PDF]

, 2009
OBJECTIVES:\ud To assess, quantify and summarise the cost of illness of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) from the societal perspective.\ud \ud METHODS:\ud Original studies reporting costs of RA or AS were searched systematically.
Ament, A.J.H.A., Boonen, A., Franke, L.C., Laar, M.A.F.J. van de, Severens, J.L.   +4 more
core   +20 more sources

Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data

Acta Dermato-Venereologica, 2022
Secukinumab, a selective interleukin (IL)-17A inhibitor, is approved for use in adult and paediatric psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
A. Gottlieb, A. Deodhar, I. McInnes, X. Baraliakos, K. Reich, S. Schreiber, W. Bao, K. Marfo, H. Richards, L. Pricop, A. Shete, V. Trivedi, Deborah Keefe, C. Papavassilis, P. Jagiello, P. Papanastasiou, P. Mease, M. Lebwohl   +17 more
semanticscholar   +1 more source

Systemic immune‐inflammation index is associated with disease activity in patients with ankylosing spondylitis

Journal of clinical laboratory analysis (Print), 2021
The systemic immune‐inflammation index (SII) is a recently developed indicator for systemic inflammatory response. We aimed to explore the association between SII and disease activity in patients with ankylosing spondylitis (AS).
Junlai Wu, Li-Fang Yan, K. Chai
semanticscholar   +1 more source